Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description

Aim: Weight gain is an important and common side effect of second generation antipsychotics (SGAs). Furthermore, these drugs can induce other side effects associated with higher cardiovascular morbidity and mortality, such as insulin resistance, diabetes or metabolic syndrome. Preliminary studies sh...

ver descrição completa

Detalhes bibliográficos
Autores: Pina-Camacho, L, Diaz-Caneja, CM, Saiz, PA, Bobes, J, Corripio, I, Grasa, E, Rodriguez-Jimenez, R, Fernandez, M, Sanjuan, J, Garcia-Lopez, A, Tapia-Casellas, C, Alvarez-Blazquez, M, Fraguas, D, Mitjans, M, Arias, B, Arango, C
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2014
País:España
Recursos:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositório:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p8858
Acesso em linha:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8858
Access Level:Acceso aberto
Palavra-chave:Antipsychotic Agents
Weight Gain
Metabolic Syndrome
Pharmacogenetics
Drug-Related Side Effects and Adverse Reactions
id ES_baaac7787cbff91d6735eb6bbd1476c7
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p8858
network_acronym_str ES
network_name_str España
repository_id_str
spelling Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample descriptionPina-Camacho, LDiaz-Caneja, CMSaiz, PABobes, JCorripio, IGrasa, ERodriguez-Jimenez, RFernandez, MSanjuan, JGarcia-Lopez, ATapia-Casellas, CAlvarez-Blazquez, MFraguas, DMitjans, MArias, BArango, CAntipsychotic AgentsWeight GainMetabolic SyndromePharmacogeneticsDrug-Related Side Effects and Adverse ReactionsAim: Weight gain is an important and common side effect of second generation antipsychotics (SGAs). Furthermore, these drugs can induce other side effects associated with higher cardiovascular morbidity and mortality, such as insulin resistance, diabetes or metabolic syndrome. Preliminary studies show that inter-individual genetic differences produce varying degrees of vulnerability to the different SGA-induced side effects. The Second-generation antipsychotic Long-term treatment Metabolic side effects (SLiM) study aims to identify clinical, environmental and genetic factors that explain inter-individual differences in weight gain and metabolic changes in drug-naive patients after six months of treatment with SGAs. Materials and methods: The SLIM study is a multicenter, observational, six-month pharmacogenetic study where a cohort of 307 drug-naive paediatric and adult patients (age range 8.8-90.1 years) and a cohort of 150 age- and sex- matched healthy controls (7.8-73.2 years) were recruited. Results: This paper describes the rationale, objectives and design of the study and provides a description of the sample at baseline. Conclusions: Results from the SUM study will provide a better understanding of the clinical, environmental, and genetic factors involved in weight gain and metabolic disturbances associated with SGA treatment. (C) 2014 SEP y SEPB. Published by Elsevier Espana, S.L.U. All rights reserved.ELSEVIER ESPANA SLU2014info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8858SPANISH JOURNAL OF PSYCHIATRY AND MENTAL HEALTHISSN: 29502861ISSNe: 19894600ISSNl: 18889891reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Españolinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p88582026-06-14T12:41:47Z
dc.title.none.fl_str_mv Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description
title Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description
spellingShingle Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description
Pina-Camacho, L
Antipsychotic Agents
Weight Gain
Metabolic Syndrome
Pharmacogenetics
Drug-Related Side Effects and Adverse Reactions
title_short Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description
title_full Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description
title_fullStr Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description
title_full_unstemmed Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description
title_sort Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description
dc.creator.none.fl_str_mv Pina-Camacho, L
Diaz-Caneja, CM
Saiz, PA
Bobes, J
Corripio, I
Grasa, E
Rodriguez-Jimenez, R
Fernandez, M
Sanjuan, J
Garcia-Lopez, A
Tapia-Casellas, C
Alvarez-Blazquez, M
Fraguas, D
Mitjans, M
Arias, B
Arango, C
author Pina-Camacho, L
author_facet Pina-Camacho, L
Diaz-Caneja, CM
Saiz, PA
Bobes, J
Corripio, I
Grasa, E
Rodriguez-Jimenez, R
Fernandez, M
Sanjuan, J
Garcia-Lopez, A
Tapia-Casellas, C
Alvarez-Blazquez, M
Fraguas, D
Mitjans, M
Arias, B
Arango, C
author_role author
author2 Diaz-Caneja, CM
Saiz, PA
Bobes, J
Corripio, I
Grasa, E
Rodriguez-Jimenez, R
Fernandez, M
Sanjuan, J
Garcia-Lopez, A
Tapia-Casellas, C
Alvarez-Blazquez, M
Fraguas, D
Mitjans, M
Arias, B
Arango, C
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Antipsychotic Agents
Weight Gain
Metabolic Syndrome
Pharmacogenetics
Drug-Related Side Effects and Adverse Reactions
topic Antipsychotic Agents
Weight Gain
Metabolic Syndrome
Pharmacogenetics
Drug-Related Side Effects and Adverse Reactions
description Aim: Weight gain is an important and common side effect of second generation antipsychotics (SGAs). Furthermore, these drugs can induce other side effects associated with higher cardiovascular morbidity and mortality, such as insulin resistance, diabetes or metabolic syndrome. Preliminary studies show that inter-individual genetic differences produce varying degrees of vulnerability to the different SGA-induced side effects. The Second-generation antipsychotic Long-term treatment Metabolic side effects (SLiM) study aims to identify clinical, environmental and genetic factors that explain inter-individual differences in weight gain and metabolic changes in drug-naive patients after six months of treatment with SGAs. Materials and methods: The SLIM study is a multicenter, observational, six-month pharmacogenetic study where a cohort of 307 drug-naive paediatric and adult patients (age range 8.8-90.1 years) and a cohort of 150 age- and sex- matched healthy controls (7.8-73.2 years) were recruited. Results: This paper describes the rationale, objectives and design of the study and provides a description of the sample at baseline. Conclusions: Results from the SUM study will provide a better understanding of the clinical, environmental, and genetic factors involved in weight gain and metabolic disturbances associated with SGA treatment. (C) 2014 SEP y SEPB. Published by Elsevier Espana, S.L.U. All rights reserved.
publishDate 2014
dc.date.none.fl_str_mv 2014
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8858
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8858
dc.language.none.fl_str_mv Español
language_invalid_str_mv Español
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER ESPANA SLU
publisher.none.fl_str_mv ELSEVIER ESPANA SLU
dc.source.none.fl_str_mv SPANISH JOURNAL OF PSYCHIATRY AND MENTAL HEALTH
ISSN: 29502861
ISSNe: 19894600
ISSNl: 18889891
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417937261035520
score 15,811543

Registros relacionados